The Effect of Obesity in Dexmedetomidine Metabolic Clearance

• Status: Unknown status
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to study the effect of obesity in dexmedetomidine pharmacokinetics and pharmacodynamic profile.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Pontificia Universidad Catolica de Chile
• Treatments: Dexmedetomidine

Criteria

Inclusion Criteria for obese patients:

• American Society of Anesthesiology classification I-III patients.

• Both genders.

• Age between 18 - 60 years.

• Body mass index higher than 40 Kg/m2.

Inclusion Criteria for non-obese patients:

• American Society of Anesthesiology classification I-II patients

• Both genders.

• Age between 18 - 60 years

• Body mass index lower than 30 Kg/m2.

Exclusion Criteria:

• Known allergy to study drugs

• Uncontrolled hypertension.

• Heart block greater than first degree.

• Chronic hepatic and kidney disease.

• Patients taking any drug acting in the central nervous system within 24 hrs before surgery.

• Patients taking drugs that induce overexpression of liver cytochrome P450-complex enzymes (Carbamazepine, Phenytoin, Phenobarbital, Rifampicin, Dexamethasone, Griseofulvin, Terbinafine, Prednisone, Hydrocortisone, Modafinil).)

• Known addiction to illicit drugs.

• Pregnancy.

• Current or past oncologic disease.